Evidence map›Paper›PMID 34678430›Full record

ArticleJournal of pharmacological and toxicological methods

Brain-derived neurotrophic factor for high-throughput evaluation of selective Sigma-1 receptor ligands.

Dhwanil A Dalwadi, Stephanie Kim, John Schetz, Derek A Schreihofer, Seongcheol Kim

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of pharmacological and toxicological methods. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Dhwanil A DalwadiDepartment of Pharmacology & Neuroscience, University of North Texas Health Science Center, Fort Worth, TX 76107, USA; Department of Medicine, Division of Gastroenterology, Oregon Health Sciences University, Portland, OR 97239, USA.
Stephanie KimDepartment of Pharmacology & Neuroscience, University of North Texas Health Science Center, Fort Worth, TX 76107, USA; University of Texas Medical Branch at Galveston, School of Medicine, Galveston, TX 77555, USA.
John SchetzDepartment of Pharmacology & Neuroscience, University of North Texas Health Science Center, Fort Worth, TX 76107, USA.
Derek A SchreihoferDepartment of Pharmacology & Neuroscience, University of North Texas Health Science Center, Fort Worth, TX 76107, USA.
Seongcheol KimDepartment of Pharmacology & Neuroscience, University of North Texas Health Science Center, Fort Worth, TX 76107, USA; Department of Cellular and Molecular Physiology, Loyola University Chicago Stritch School of Medicine, Maywood, IL 60153, USA. Electronic address: skim46@luc.edu.
University of North Texas · US

Funding

Repositioning Drugs to Treat Ischemic Stroke at Delayed Time PointsR21NS095271 · NINDS · UNIVERSITY OF NORTH TEXAS HLTH SCI CTR · PI SCHREIHOFER, DEREK A · 2016 to 2017
$402k
NINDS NIH HHS R21 NS095271
6 · The paper itself

Abstract

The Sigma-1 receptor (S1R) is an endoplasmic reticulum (ER) chaperone protein that has been implicated in attenuating inflammatory stress-mediated brain injuries. Selective S1R agonists represent a new class of therapeutic agent for treating neuropsychiatric and neurodegenerative disorders, however, to date, no S1R ligand has been approved for therapeutic purposes. We used three potential methods on known and potential S1R ligands to develop an unambiguous high-throughput cell screen for S1R activity. We screened known and potential S1R ligands using radioligand binding and previously reported markers of S1R activity including BDNF release, modulation of IP

Indexed as

Brain-Derived Neurotrophic FactorReceptors, sigmaEndoplasmic ReticulumLigandsSigma-1 ReceptorBrain-Derived Neurotrophic FactorLigandsReceptors, sigmaSigma-1 ReceptorBDNFDrug repurposingScreeningSigma 1 receptorSigma 2 receptor

Identifiers

PMID34678430
PMCPMC9358981
OpenAlexW3207743646

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.